Carfilzomib, a second-generation proteasome inhibitor, is approved for the treatment of relapsed or refractory multiple myeloma, with cardiovascular toxicity being the most common concern.
A combination of ipratropium bromide (IB) and salbutamol is commonly used to treat asthma in children and adolescents; however, there has been a lack of consistency in its usage in clinical practice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results